Can I Take Vitamin C With Warfarin

Treatment

Approach Considerations

All patients with signs of active bleeding or at significant risk of life-threatening hemorrhage require admission to the hospital. Suicidal ingestions require psychiatric evaluation, as well as 48-72 hours of observation to monitor for anticoagulation. Significant superwarfarin poisoning may require many weeks of vitamin K₁ therapy.^[15]

With regard to prehospital emergency care, initiate usual supportive measures, including intravenous (IV) access if any suggestion of remote or active bleeding is evident. After an acute intentional ingestion, activated charcoal should be considered for clinically significant ingestions if it can be administered within an hour or two of the ingestion. Infuse crystalloid solution if signs of significant blood loss are present.

Emergency Department Care

Initiate usual advanced supportive measures. Evaluate for current or remote bleeding with a thorough physical examination, including a rectal examination as indicated to check for occult gastrointestinal (GI) bleeding. If significant bleeding has occurred and the patient is unstable, be prepared to treat the patient with transfusions of packed red blood cells (RBCs), fresh frozen plasma (FFP), and intravenous (IV)/oral vitamin K₁ as first-line therapy.^[16]Further evaluation varies according to the situation.

Warfarin and superwarfarin ingestions may be acute or chronic. In either situation, determine whether the ingestion was unintentional or intentional and whether the patient requires long-term anticoagulation (eg, mechanical heart valve, chronic atrial fibrillation).

Acute ingestion

For acute ingestions, generally no evidence of bleeding is present on the initial clinical examination, unless the ingestion occurred more than 12-24 hours before emergency department (ED) presentation.

Obtain a baseline prothrombin time and international normalized ratio (PT/INR) and make arrangements for a repeat measurement in 24-48 hours. Administer activated charcoal for recent (within the last 1 - 2 hours) clinically significant ingestions. Gastric lavage is unnecessary if rapid administration of activated charcoal is feasible. Do not induce emesis.

Treat any co-ingestions, evaluate the patient for suicidal intention, and refer appropriately. Avoid drugs that may enhance bleeding or decrease metabolism of the anticoagulant.

Do not administer vitamin K₁ prophylactically because (1) it is not needed in most patients, and (2) its presence masks the onset of anticoagulant effects in the few patients who do require prolonged treatment and follow-up care.

If the PT is elevated, treatment with vitamin K₁ is appropriate; 10 mg orally is a reasonable daily dose. Since the pharmacologic effects of warfarin wear off within days, otherwise healthy patients with acute warfarin ingestions do not need supplemental vitamin K₁ for more than several days. In the setting of superwarfarin-induced coagulopathies, 50-200 mg daily is recommended, and the duration of therapy may be many weeks.

Note that if a patient has a critical need for ongoing anticoagulation (eg, mechanical heart valve), heparin can be given as a temporary measure while the effects of warfarin are fully reversed.

Chronic intoxication

Chronic intoxication resulting from the therapeutic use of warfarin can be evaluated with a careful physical examination and a measurement of the PT and INR.

Chronic ingestions of rodenticide superwarfarin may also be intentional (eg, Munchhausen syndrome) or can occur in the setting of child abuse (Munchhausen by proxy).^[17]These patients should be admitted for psychiatric or protective services evaluation.

If the INR is higher than therapeutic levels but less than 5 and the patient is not bleeding, the dose of warfarin may be lowered or the next dose may be omitted. If the patient requires more rapid reversal (eg, elective surgery), administer 1-2.5 mg of vitamin K₁ orally with the expectation that the INR will begin to fall within 8 hours, with a maximal effect in about 24 hours.

If the INR is higher than 5 but less than 9 and the patient is not actively bleeding, withhold warfarin for the next 1 or 2 doses, monitor the INR more frequently, and resume therapy at a lower dose when the INR is at the therapeutic level.

Another therapeutic approach would be to withhold 1 dose of warfarin and orally administer vitamin K₁, 1-2.5 mg, particularly if the patient is at increased risk of bleeding. For more rapid reversal (eg, urgent surgery), administer vitamin K₁, 2.5-5 mg, orally (expected reduction of the INR should occur in about 24 h).

If the INR is higher than 9 and the patient is not bleeding, oral vitamin K₁ (2.5 - 5 mg) may be administered with the expectation of a subtstantial reduction in the INR in 24 - 48 hours. In the setting of superwarfarin-induced coagulopathies, daily doses of vitamin K₁ in the range of 50-200 mg is recommended.

Treatment of serious hemorrhage

Active, serious hemorrhage should be treated with four-factor prothrombin complex concentrate (PCC), if available.^[12]While costly, an essential advantage PCC confers to emergency care is that, in contrast to FFP, it results in a more rapid reversal of coagulopathy and does not require thawing or blood group typing. Additionally,it has a reduced risk of volume overload, transfusion-related acute lung injury, transfusion reactions, and infectious disease transmission. Despite these advantages, no mortality benefit has been proven for PCC compared with FFP.

Alternatively, recombinant factor VIIa (rFVIIa) has been reported to be effective in rapidly lowering INR due to warfarin toxicity and may be considered if PCC is not available. FFP is effective at lowering the INR and was historically first-line therapy for warfarin toxicity with serious or life-threatening bleeding, although it has now been superceded by PCC, which lowers the INR more rapidly. If PCC or rFVIIa are not available, 4 units of FFP may be administered instead.

Administer vitamin K₁, 10 mg, by slow IV infusion. Using IV vitamin K₁ is rarely associated with an anaphylactoid reaction. If that occurs, the infusion should be stopped for 15 minutes, diphenhydramine administered, and vitamin K₁ then restarted at a lower infusion rate.

Consultations and Transfer

Since most warfarin and superwarfarin exposures result in minor or no significant effects, regional poison control centers can aid in decreasing the referral of patients to health care facilities and in reducing the performance of unnecessary laboratory tests in minor, unintentional exposures. The poison centers and clinical toxicologists may be helpful in evaluating a large anticoagulant overdose and can assist with long-term follow-up care after ingestion of a superwarfarin.

Obtaining a psychiatric referral is appropriate for intentional ingestions. Contact child welfare or protective services if child abuse is suspected.

The patient's primary care provider or the local coagulation clinic is an appropriate referral if an unintentional overdose occurs and the patient is considered to be at low risk for bleeding complications.

Consulting a neurosurgeon is appropriate for intracranial hemorrhage. Consulting a gastroenterologist is appropriate for gastrointestinal hemorrhage.

If the patient has any type of hemorrhage that the current facility is not capable of managing appropriately, transfer to a higher level of care is indicated.

Follow-Up

Patients who are already on warfarin, who have had an unintentional overdose, and who are hemodynamically stable with no evidence of active bleeding can follow up with their regular source of anticoagulation care. The frequency of routine INR monitoring for patients on stable warfarin dosing may be able to be extended further than every 4 weeks, depending on future studies.^[18]

With acute warfarin ingestions, discharge instructions must address the risk of rebound coagulopathy, which may occur as long as 3 days afterward. Patients need to understand the importance of completing a full course of vitamin K1.^[19]

Children with acute unintentional ingestions can be discharged home with follow-up care by their pediatrician in the office or by telephone at 48 hours. Most authorities no longer recommend routine follow-up PT measurement, because the incidence of significant anticoagulation in children after accidental exposure is extremely low.^{[8, 20, 21]}

Anderson IB. Warfarin and related rodenticides. Olson KR, ed. Poisoning & Drug Overdose. 6th ed. The McGraw-Hill Companies; 2012. 409-11.
Chen BC, Su M. Antithrombotics. Hoffman RS, Howland MA, Lewin NA, Nelson LS, Goldfrank LR, eds. Goldfrank's Toxicologic Emergencies. 10th ed. McGraw-Hill Education; 2015.
Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001 Jan. 119(1 Suppl):8S-21S. [Medline].
Olmos V, Lopez CM. Brodifacoum poisoning with toxicokinetic data. Clin Toxicol (Phila). 2007. 45(5):487-9. [Medline].
Baillargeon J, Holmes HM, Lin YL, Raji MA, Sharma G, Kuo YF. Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. Am J Med. 2012 Feb. 125(2):183-9. [Medline].
Lane MA, Zeringue A, McDonald JR. Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans. Am J Med. 2014 Jul. 127(7):657-663.e2. [Medline]. [Full Text].
Gummin DD, Mowry JB, Spyker DA, Brooks DE, Beuhler MC, Rivers LJ, et al. 2018 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 36th Annual Report. Clin Toxicol (Phila). 2019 Dec. 57 (12):1220-1413. [Medline]. [Full Text].
Ingels M, Lai C, Tai W, Manning BH, Rangan C, Williams SR, et al. A prospective study of acute, unintentional, pediatric superwarfarin ingestions managed without decontamination. Ann Emerg Med. 2002 Jul. 40(1):73-8. [Medline].
Gitter MJ, Jaeger TM, Petterson TM, et al. Bleeding and thromboembolism during anticoagulant therapy: a population- based study in Rochester, Minnesota. Mayo Clin Proc. 1995 Aug. 70(8):725-33. [Medline].
[Guideline] Caravati EM, Erdman AR, Scharman EJ, Woolf AD, Chyka PA, Cobaugh DJ. Long-acting anticoagulant rodenticide poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007. 45(1):1-22. [Medline].
Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014 Mar 18. 129(11):1196-203. [Medline].
Schulman S, Furie B. How I treat poisoning with vitamin K antagonists. Blood. 2015 Jan 15. 125 (3):438-42. [Medline]. [Full Text].
Miller MA, Levy PD, Hile D. Rapid identification of surreptitious brodifacoum poisoning by analysis of vitamin K-dependent factor activity. Am J Emerg Med. 2006 May. 24(3):383. [Medline].
Spahr JE, Maul JS, Rodgers GM. Superwarfarin poisoning: a report of two cases and review of the literature. Am J Hematol. 2007 Jul. 82(7):656-60. [Medline].
Tsutaoka BT, Miller M, Fung SM, et.al. Superwarfarin and glass ingestion with prolonged coagulopathy requiring high-dose vitamin K1 therapy. Pharmacotherapy. 2003 Sep. 23(9):1186-9. [Medline].
Wang Y, Kotik V, Fahim G, Alagusundaramoorthy S, Eltawansy SA, Mathis S, et al. Treatment of brodifacoum overdose with prothrombin complex concentrate. Am J Health Syst Pharm. 2016 Jan 1. 73 (1):e14-7. [Medline].
Chua JD, Friedenberg WR. Superwarfarin poisoning. Arch Intern Med. 1998 Sep 28. 158(17):1929-32. [Medline].
Schulman S, Parpia S, Stewart C, Rudd-Scott L, Julian JA, Levine M. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med. 2011 Nov 15. 155(10):653-9. [Medline].
Berling I, Mostafa A, Grice JE, Roberts MS, Isbister GK. Warfarin Poisoning with Delayed Rebound Toxicity. J Emerg Med. 2017 Feb. 52 (2):194-196. [Medline].
Mullins ME, Brands CL, Daya MR. Unintentional pediatric superwarfarin exposures: do we really need a prothrombin time?. Pediatrics. 2000 Feb. 105(2):402-4. [Medline].
Smolinske SC, Scherger DL, Kearns PS, et al. Superwarfarin poisoning in children: a prospective study. Pediatrics. 1989 Sep. 84(3):490-4. [Medline].
[Guideline] Witt DM, Nieuwlaat R, Clark NP, Ansell J, Holbrook A, Skov J, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018 Nov 27. 2 (22):3257-3291. [Medline]. [Full Text].
Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa. Ann Intern Med. 2002. 137(11):884-888. [Medline].
Ilyas C, Beyer GM, Dutton RP, Scalea TM, Hess JR. Recombinant factor VIIa for warfarin-associated intracranial bleeding. J Clin Anesth. 2008 Jun. 20(4):276-9. [Medline].
Nishijima DK, Dager WE, Schrot RJ, Holmes JF. The efficacy of factor VIIa in emergency department patients with warfarin use and traumatic intracranial hemorrhage. Acad Emerg Med. 2010 Mar. 17(3):244-51. [Medline].
Huttner HB, Schellinger PD, Hartmann M, Köhrmann M, Juettler E, Wikner J, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006 Jun. 37(6):1465-70. [Medline].
Kalina M, Tinkoff G, Gbadebo A, Veneri P, Fulda G. A protocol for the rapid normalization of INR in trauma patients with intracranial hemorrhage on prescribed warfarin therapy. Am Surg. 2008 Sep. 74(9):858-61. [Medline].
Dezee KJ, Shimeall WT, Douglas KM, Shumway NM, O'malley PG. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med. 2006 Feb 27. 166(4):391-7. [Medline].
Bershad EM, Suarez JI. Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature. Neurocrit Care. 2010 Jun. 12(3):403-13. [Medline].

Author

Kent R Olson, MD, FACEP Clinical Professor of Medicine and Pharmacy, University of California, San Francisco, School of Medicine; Medical Director, San Francisco Division, California Poison Control System

Kent R Olson, MD, FACEP is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Medical Toxicology